Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences ADME and Predictive Toxicology

Christopher Goldring's Biography

Christopher Goldring, Senior Lecturer, University of Liverpool

B.Sc. Biochemistry, Liverpool John Moores University, 1986; Ph.D. Biochemistry, Guy’s Hospital, London, 1991; PGCert in Learning and Tecahing, University of Liverpool, 2011; Wellcome Trust Travelling Research Scholar to Xi’an University, China, 1988-1989, Erasmus Visiting Scholar at the University of Siena, Italy, 1991. Previously carried out research and lectured at the Ecole Pratique des Hautes Etudes, University of Bourgogne, France and the Department of Nephrology, Bern University Hospital, Switzerland, before moving to The Drug Safety Group at the University of Liverpool, in 1999. He now leads the molecular and cellular toxicology group within the MRC Centre for Drug Safety Science (CDSS) ( a leading UK centre led from the University of Liverpool, with a critical mass of scientists studying mechanisms of adverse reactions to drugs, and which is the coordinator of the new Mechanism based Improved Prediction of Drug-Induced Liver Injury (MIP-DILI) IMI programme. CG has nearly twenty years of experience of molecular bioanalysis, working with cell culture and in vivo models, and has largely focused on understanding transcriptional control in the liver. He has >60 journal and conference papers published to date. He has current MRC, Wellcome Trust, BBSRC, and Stem Cells for Safer Medicines support. He has been a panel member of Biotech grant committees for Enterprise Ireland, and he leads teaching programmes on Safety Pharmacology and Stem Cells in the Innovative Medicines Initiative Safescimet training programme. 

Christopher Goldring Image

Evaluation and Adverse Consequences of Metabolic Bioactivation

Thursday, 11 April 2013 at 16:30

Add to Calendar ▼2013-04-11 16:30:002013-04-11 17:30:00Europe/LondonEvaluation and Adverse Consequences of Metabolic Bioactivation ADME and Predictive Toxicology in Barcelona, SpainBarcelona,

This talk will highlight the work carried out at the MRC Centre for Drug Safety Science in the U.K. and in other laboratories, to evaluate the adverse consequences of metabolic bioactivation of drugs, how we adapt to drug exposure, and how the use of biomarkers may help us to bridge our understanding between different established and emerging experimental models.

Add to Calendar ▼2013-04-11 00:00:002013-04-12 00:00:00Europe/LondonADME and Predictive ToxicologyADME and Predictive Toxicology in Barcelona, SpainBarcelona,